Neurocrine Biosciences (NBIX) Surges 13% After Strong Q1 Results

 

• Neurocrine Biosciences (NBIX, Financial) stock surged 13% post Q1 earnings, beating forecasts.
• The company's sales projection for Ingrezza remains solid at $2.5B-$2.6B.
• Analysts foresee a 40.64% upside with a strong "Outperform" rating.

Neurocrine Biosciences (NBIX) shares saw an impressive rise of approximately 13% in after-hours trading, sparked by the release of their robust Q1 earnings report. Not only did the report exceed expectations, but it also reaffirmed the company's promising 2025 forecasts. Particularly notable is Neurocrine's projection for Ingrezza, its leading treatment for tardive dyskinesia, which is expected to achieve sales between $2.5 billion and $2.6 billion. As of the quarter's end, the company's cash reserves stood strong at $1.76 billion

https://www.gurufocus.com/news/2830776/neurocrine-biosciences-nbix-surges-13-after-strong-q1-results